EuroTimes Breaking News
Date Posted 15/12/2009
Alcon to enter surgical glaucoma market by acquiring Optonol
Alcon has entered into an agreement to acquire Optonol, Ltd, the medical device company that develops, manufactures and markets novel miniature surgical implants used to lower intraocular pressure (IOP) in patients with glaucoma. With this acquisition, Alcon will acquire Optonol's Ex-PRESS(TM) Mini Glaucoma Shunt.
Alcon says this agreement will complement their pharmaceutical products that lower IOP in patients with glaucoma and ocular hypertension.
"This transaction demonstrates Alcon's strong commitment to providing physicians with comprehensive treatment options for patients with glaucoma, the world's second leading cause of blindness," said Robert Warner, Alcon's vice-president of US pharmaceutical products. "The closing of the acquisition is subject to customary closing conditions and the receipt of required regulatory approvals and is expected to occur by the end of the first quarter of 2010."





eTIMES newsletter
eTIMES is a new bi-monthly newsletter with the latest breaking news from the ESCRS and the world of ophthalmology.
Media Guide 2010
Results from our readership survey plus information about advertising in EuroTimes
Podcasts
Eye Contact features interviews with key opinion leaders in the world of ophthalmology
Thursday, 09 September 2010
www.eurotimes.org